The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor

The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor

Abstract Background Multiple myeloma is a plasma cell tumour with approximately 5500 new cases in the UK each year. Ixazomib is a next generation inhibitor of the 20S proteasome and is thought to be an effective treatment for those who have relapsed from bortezomib. The combination of cyclophosphami...

Full description

Bibliographic Details
Main Authors: Samantha Hinsley, Katrina Walker, Debbie Sherratt, Lucy Bailey, Sadie Reed, Louise Flanagan, Sophie McKee, Fiona Brudenell Straw, Bryony Dawkins, David Meads, Holger W. Auner, Martin F. Kaiser, Mark Cook, Sarah Brown, Gordon Cook, on behalf of the Myeloma UK Clinical Trials Network
Format: Article
Language:English
Published: BMC 2020-10-01
Series:Trials
Online Access:http://link.springer.com/article/10.1186/s13063-020-04739-8

Internet

http://link.springer.com/article/10.1186/s13063-020-04739-8

Similar Items